Track topics on Twitter Track topics that are important to you
ArQule has created a new technology platform for the discovery and production of novel chemical compounds with commercial potential. The Company has developed proprietary technologies for the identification and optimizationof drug development candidates and agrochemicals. Using combinatorial chemistry, a modular building block approach to the development of compounds, structure-guided compound design, high speed parallel chemical synthesis and
information technology, the Company rapidly develops large, diverse collections of compounds that have the potential to be biologically active. To date, the Company has entered into collaborative arrangements with Abbott Laboratories, Monsanto Company, Amersham Pharmacia Biotech AB, Roche Bioscience, Solvay Duphar B.V., American Homes Products Corporation, Inc. and Sankyo Company, Ltd. and has formed joint discovery programs with many biotechnology companies.
19 Presidential Way
United States of America
Phone: 781 994 0300
WASHINGTON (dpa-AFX) - Biopharmaceutical company ArQule, Inc. (ARQL) announced Tuesday that the first patient has been dosed in a phase 1a/b trial with its BTK inhibitor, ARQ 531, in patients with...
In its second private placement in two months, cancer and rare disease drug developer ArQule Inc. netted $9.3mm through the sale of 8,370 Series A convertible preferred shares at $1,135; each preferre...
ArQule's orphan drug-tagged miransertib received rare pediatric disease designation from the FDA. -More-
ArQule Inc. (cancer and rare disease drug development) netted $15.5mm through a private placement of 13.9mm common shares at $1.14 (a 4% premium) and four-year warrants to purchase 3.1mm shares at $1....
Trial is enrolling patients refractory to standard of care, including ibrutinib BURLINGTON, Mass.--(BUSINESS WIRE)--ArQule, Inc. (Nasdaq: ARQL) today announced that the first patient ...
BURLINGTON, Mass.--(BUSINESS WIRE) November 1, 2017 -- ArQule, Inc. (Nasdaq: ARQL) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to mi...
East Coast rare disease and oncology specialist ArQule has been awarded rare pediatric disease designation…
ArQule is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Companyâs targeted, broad-spectrum produ...
On December 19, 2008, ArQule and Daiichi Sankyo, Co., Ltd. signed a license, co-development and co-commercialization agreement to co-develop tivantinib in the U.S., Europe, South ...
ArQule has created a new technology platform for the discovery and production of novel chemical compounds with commercial potential. The Company has developed proprietary technologies for the identifi...
PRAECIS PHARMACEUTICALS INCORPORATED is a biopharmaceutical company focused on the discovery and development of novel compounds to address unmet medical needs or improve existing therapies.PRAECIS has...
Founded in 2008 by the Axis Biotec Brasilâ¢ group (www.axisbiotec.com.br), PharmaPraxis has incorporated technologies, and will develop and launch biologic products in Brazil....
We have published hundreds of ArQule Incorporated news stories on BioPortfolio along with dozens of ArQule Incorporated Clinical Trials and PubMed Articles about ArQule Incorporated for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of ArQule Incorporated Companies in our database. You can also find out about relevant ArQule Incorporated Drugs and Medications on this site too.
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...